Core Viewpoint - HOPE Therapeutics, Inc. has signed a definitive agreement to acquire Dura Medical, enhancing its interventional psychiatry network on Florida's west coast, with Dura being revenue-generating and EBITDA positive [1][9]. Company Overview - HOPE Therapeutics is focused on developing a network of interventional psychiatry clinics that utilize psychedelic medications, including ketamine and Spravato®, combined with Transcranial Magnetic Stimulation (TMS) and other therapies for patients with suicidal depression and related disorders [7]. - NRx Pharmaceuticals, the parent company of HOPE, is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders, including suicidal bipolar depression and chronic pain [8]. Acquisition Details - Dura Medical, founded in 2018, specializes in a precision approach to treating mental health and chronic pain, offering services such as Ketamine Infusion Therapy and TMS [2][9]. - The acquisition is expected to provide comprehensive services to patients and is part of HOPE's strategy to expand its operations in Florida [1][9]. - The intended closing of the acquisition is subject to financial audits, regulatory approvals, and standard closing conditions [6]. Leadership and Mission - Stephen Durand, the founder of Dura Medical, will serve as the Director of Florida Clinic Operations for HOPE, emphasizing the mission to reduce suicide rates and treat over 10,000 individuals by 2026 [4][3]. - The collaboration aims to integrate Dura's commitment to patient care for both civilians and veterans into HOPE's network [5][9]. Services Offered - Dura Medical provides a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and TMS, catering to both veteran and civilian patients [9]. - The clinics utilize advanced interventional psychiatry procedures to address various mental health issues, including depression, suicidality, PTSD, and anxiety [2]. Future Plans - HOPE Therapeutics plans to expand its service offerings and enhance its operational capabilities through the acquisition of Dura Medical and the previously announced Neurospa network [1][9]. - The company is also pursuing the development of NRX-101, an investigational therapy for suicidal treatment-resistant bipolar depression, with plans to file for Accelerated Approval [8][10].